Use of a kinase inhibitor for the treatment of particular resistant tumors

Use of a kinase inhibitor for the treatment of particular resistant tumors

The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Fancelli, Daniele, Isacchi, Antonella, Modugno, Michele, Moll, Juergen, Rusconi, Luisa, Soncini, Chiara, Lupi, Rosita
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Fancelli, Daniele
Isacchi, Antonella
Modugno, Michele
Moll, Juergen
Rusconi, Luisa
Soncini, Chiara
Lupi, Rosita
description The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.
format Patent
fullrecord <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_08084455</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>08084455</sourcerecordid><originalsourceid>FETCH-uspatents_grants_080844553</originalsourceid><addsrcrecordid>eNrjZPAKLU5VyE9TSFTIzsxLBLIz8zIykzJL8osU0oC4JCNVoaQoNbEkNzWvBKSuILGoJDO5NCexSKEotTizuCQRKF5SmptfVMzDwJqWmFOcyguluRkU3FxDnD10S4sLEkuA-ovj04sSQZSBhYGFiYmpqTERSgDREjYY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Use of a kinase inhibitor for the treatment of particular resistant tumors</title><source>USPTO Issued Patents</source><creator>Fancelli, Daniele ; Isacchi, Antonella ; Modugno, Michele ; Moll, Juergen ; Rusconi, Luisa ; Soncini, Chiara ; Lupi, Rosita</creator><creatorcontrib>Fancelli, Daniele ; Isacchi, Antonella ; Modugno, Michele ; Moll, Juergen ; Rusconi, Luisa ; Soncini, Chiara ; Lupi, Rosita ; Nerviano Medical Sciences S.r.l</creatorcontrib><description>The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.</description><language>eng</language><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8084455$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,776,798,881,64012</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8084455$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Fancelli, Daniele</creatorcontrib><creatorcontrib>Isacchi, Antonella</creatorcontrib><creatorcontrib>Modugno, Michele</creatorcontrib><creatorcontrib>Moll, Juergen</creatorcontrib><creatorcontrib>Rusconi, Luisa</creatorcontrib><creatorcontrib>Soncini, Chiara</creatorcontrib><creatorcontrib>Lupi, Rosita</creatorcontrib><creatorcontrib>Nerviano Medical Sciences S.r.l</creatorcontrib><title>Use of a kinase inhibitor for the treatment of particular resistant tumors</title><description>The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2011</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNrjZPAKLU5VyE9TSFTIzsxLBLIz8zIykzJL8osU0oC4JCNVoaQoNbEkNzWvBKSuILGoJDO5NCexSKEotTizuCQRKF5SmptfVMzDwJqWmFOcyguluRkU3FxDnD10S4sLEkuA-ovj04sSQZSBhYGFiYmpqTERSgDREjYY</recordid><startdate>20111227</startdate><enddate>20111227</enddate><creator>Fancelli, Daniele</creator><creator>Isacchi, Antonella</creator><creator>Modugno, Michele</creator><creator>Moll, Juergen</creator><creator>Rusconi, Luisa</creator><creator>Soncini, Chiara</creator><creator>Lupi, Rosita</creator><scope>EFH</scope></search><sort><creationdate>20111227</creationdate><title>Use of a kinase inhibitor for the treatment of particular resistant tumors</title><author>Fancelli, Daniele ; Isacchi, Antonella ; Modugno, Michele ; Moll, Juergen ; Rusconi, Luisa ; Soncini, Chiara ; Lupi, Rosita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_080844553</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Fancelli, Daniele</creatorcontrib><creatorcontrib>Isacchi, Antonella</creatorcontrib><creatorcontrib>Modugno, Michele</creatorcontrib><creatorcontrib>Moll, Juergen</creatorcontrib><creatorcontrib>Rusconi, Luisa</creatorcontrib><creatorcontrib>Soncini, Chiara</creatorcontrib><creatorcontrib>Lupi, Rosita</creatorcontrib><creatorcontrib>Nerviano Medical Sciences S.r.l</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Fancelli, Daniele</au><au>Isacchi, Antonella</au><au>Modugno, Michele</au><au>Moll, Juergen</au><au>Rusconi, Luisa</au><au>Soncini, Chiara</au><au>Lupi, Rosita</au><aucorp>Nerviano Medical Sciences S.r.l</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Use of a kinase inhibitor for the treatment of particular resistant tumors</title><date>2011-12-27</date><risdate>2011</risdate><abstract>The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_uspatents_grants_08084455
source USPTO Issued Patents
title Use of a kinase inhibitor for the treatment of particular resistant tumors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T02%3A45%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Fancelli,%20Daniele&rft.aucorp=Nerviano%20Medical%20Sciences%20S.r.l&rft.date=2011-12-27&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E08084455%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true